ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2089

The Implication of Skin Involvement on Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients

Alicia Van1, Vibeke Strand2, Jiandong Su1, Nicole Anderson1, Cheryl F Rosen3, Sherief Marzouk4, Lee S Simon5 and Zahi Touma1, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 2Stanford University School of Medicine, Stanford, CA, 3University of Toronto, Toronto, ON, Canada, 4University Health Network, University of Toronto, Toronto, ON, Canada, 5SDG LLC, West Newton, MA

Meeting: ACR Convergence 2022

Keywords: Damage Index, Disease Activity, SF36

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Skin involvement in Systemic Lupus Erythematosus (SLE) occurs in 50-85% of patients making it one of the most commonly affected organs in SLE. Previous studies have shown that SLE has a large impact on Health-Related Quality of Life (HRQoL). A more in-depth investigation of skin involvement is required, as many patients feel self-conscious about their appearance when manifestations such as alopecia, malar and discoid rashes are present. Our goal for this study was to determine the HRQoL in SLE patients with skin involvement compared with other organ system involvement

Methods: Patients attending a single centre underwent HRQoL assessment, using the 36-Item Short Form Health Survey (SF-36). Patients with > ten years of follow up were included in the study. Organ involvement was based on the 10 domains of the EULAR/ACR classification criteria and the 9 domains of cumulative 10-year SLE Disease Activity Index 2000 (SLEDAI-2K) prior to index date (latest clinic visit). Patients were stratified based on ever having skin involvement or never having skin involvement in the past ten years. Descriptive and regression analyses were performed, adjusted for sociodemographic, organ damage by SLICC/ACR Damage Index (SDI) and fibromyalgia status; LASSO (least absolute shrinkage and selection operator) variable selection method in multivariable regression was used (multi-collinearity was assessed). Spydergrams were developed to characterize SF-36 domains in both groups. As a sensitivity analysis, we grouped patients into those with and without current skin involvement based on SLEDAI-2K domains captured at the index visit and applied the same analysis as above.

Results: Among 760 patients, 380 (89.5%) were female, mean age at index visit was 51.5±15.5 and mean disease duration was 21.8 ± 11.5 years. Table 1 shows patient characteristics at index date. Patients with skin involvement had significantly lower SF-36 scores than those without in Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality and Social Functioning domains (Figure 1). The Physical Component Summary (PCS) score was significantly lower in SLE patients with skin involvement compared to those without (38.5 ± 12.1 vs 43.3 ± 11.4; P< 0.001), while differences in Mental Component Summary (MCS) scores did not reach significance.

In the sensitivity analysis, again patients with current skin involvement had significantly lower SF-36 scores than those without in Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality and Social Functioning domains (data not shown).

Univariate regressions showed skin involvement was associated with most of the 8 SF-36 domains, while in the multivariate regression only two SF-36 domains remained in the final model. Multivariable regression showed Social Functioning was negatively associated with skin involvement (Table 2).

Conclusion: Skin involvement in SLE is associated with lower health-related quality of life by SF-36 compared to SLE patients with other organ involvement. Early identification of patients with skin involvement may facilitate earlier and more robust coping strategies for this group of patients.

Supporting image 1

Table 1. Cohort Characteristics (n=760) at index date

Supporting image 2

Table 2. Univariate and multivariate analyses to study the association of ever skin involvement with each of the eight SF_36 domains

Supporting image 3

Figure 1. Comparison of SF_36 domains scores in SLE patients with and without skin involvement


Disclosures: A. Van, None; V. Strand, AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb(BMS), Boehringer-Ingelheim, Chemocentryx, Celltrion, Genentech/Roche, Gilead, GlaxoSmithKlein(GSK), Inmedix, Janssen, Kiniksa, Merck/MSD, Novartis, Pfizer, Regeneron Pharmaceuticals, Rheos, R-Pharma, Samsung, Sandoz, Sanofi, Scipher, Setpoint, Spherix, Aria, Bioventus, Blackrock, Equilium, Glenmark, Horizon, Kypha, Lilly, MiMedx, Sorrento, Tonix, Priovant; J. Su, None; N. Anderson, None; C. Rosen, Eli Lilly, Novartis, Amgen, Bristol-Myers Squibb(BMS), UCB, AbbVie/Abbott; S. Marzouk, None; L. Simon, None; Z. Touma, None.

To cite this abstract in AMA style:

Van A, Strand V, Su J, Anderson N, Rosen C, Marzouk S, Simon L, Touma Z. The Implication of Skin Involvement on Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-implication-of-skin-involvement-on-health-related-quality-of-life-hrqol-in-systemic-lupus-erythematosus-sle-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-implication-of-skin-involvement-on-health-related-quality-of-life-hrqol-in-systemic-lupus-erythematosus-sle-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology